- Home
- CODA vs PRQR Comparison
CODA vs PRQR Comparison
Compare CODA & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CODA | PRQR |
|---|---|---|
| Founded | 1994 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.4M | 167.5M |
| IPO Year | 2007 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CODA | PRQR |
|---|---|---|
| Price | $12.10 | $1.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.80 |
| AVG Volume (30 Days) | 155.3K | ★ 642.4K |
| Earning Date | 03-17-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.62 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $20,316,161.00 | N/A |
| Revenue This Year | $18.28 | N/A |
| Revenue Next Year | $12.62 | $13.92 |
| P/E Ratio | $150.38 | ★ N/A |
| Revenue Growth | ★ 4.98 | N/A |
| 52 Week Low | $5.98 | $1.33 |
| 52 Week High | $18.00 | $3.10 |
Technical Indicators
Market Signals| Indicator | CODA | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 45.79 | 47.77 |
| Support Level | $10.87 | $1.34 |
| Resistance Level | $12.22 | $1.80 |
| Average True Range (ATR) | 0.65 | 0.17 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 36.42 | 18.27 |
Price Performance
Historical ComparisonAbout CODA Coda Octopus Group Inc.
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company operates in three distinct business segments: the Marine Technology business, Acoustic Sensors and Material Business and the Defense Engineering Services Business. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.